The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Biogen provides community update on Spinraza European pricing

    Following a request by SMA Europe, Biogen held a conference call on Friday 9th June regarding the company’s pricing policy for Spinraza™. In response to a subsequent request to share a summary of the discussion, Biogen has provided the following update.  Please see below for a community update on the call. Dear members of the […]


  2. European Commission grants Biogen license for Spinraza

    The approval of SPINRAZA by the European Commission is very good news for our community. Patients and families affected by SMA in Europe may now have a far brighter future than before SPINRAZA was available. However, we are aware this is the first step in SMA treatment development. We are grateful for the perseverance of […]


  3. Spinraza improves motor function in children with later-onset SMA

    Biogen presented data from the end of the Phase 3 study on Spinraza™ (CHERISH) at a plenary session of the American Academy of Neurology (AAN) annual meeting in Boston on 24th April 2017. This data demonstrated a highly statistically significant and clinically meaningful improvement in motor function in children with later-onset (most likely to develop […]